TABLE 1.
Features of the Meta-analysis
| Study | Drug | No. in Drug Group | No. in Placebo Group | Mean Age | % Male | DSM Edition |
|---|---|---|---|---|---|---|
| Conners, 1980 | MPH | 20 | 20 | 12 | 95 | |
| Taylor, 1987 | MPH | 37 | 37 | 9 | 100 | 3 |
| Klorman, 1994 | MPH | 44 | 44 | 9 | 84 | 3R |
| Conners, 1996 | Bupropion | 61 | 31 | 9 | 90 | 3R |
| Schachar, 1997 | MPH | 37 | 29 | 8 | 77 | 3R |
| Manos, 1999 | MAS | 42 | 42 | 10 | 79 | 4 |
| Manos, 1999 | MPH | 42 | 42 | 10 | 79 | 4 |
| Zeiner, 1999 | MPH | 36 | 36 | 9 | 100 | 3R |
| Pliszka, 2000 | MAS | 20 | 18 | 8 | NA | NA |
| Pliszka, 2000 | MPH | 20 | 18 | 8 | NA | NA |
| James, 2001 | MAS | 35 | 35 | 9 | 60 | 4 |
| James, 2001 | d-Amph | 35 | 35 | 9 | 60 | 4 |
| James, 2001 | d-Amph ER | 35 | 35 | 9 | 60 | 4 |
| Wolraich, 2001 | MPH | 97 | 90 | 9 | 87 | 4 |
| Wolraich, 2001 | OROS MPH | 95 | 90 | 9 | 78 | 4 |
| Michelson, 2001 | Atomoxetine | 82 | 83 | 11 | 72 | 4 |
| Michelson, 2002 | Atomoxetine | 84 | 83 | 10 | 71 | 4 |
| Biederman, 2002 | Atomoxetine | 31 | 21 | 10 | 0 | 4 |
| Biederman, 2002 | MAS-XR | 120 | 203 | 9 | 80 | 4 |
| Greenhill, 2002 | MPH-MR | 155 | 159 | 9 | 83 | 4 |
| Spencer, 2002 | Atomoxetine | 49 | 47 | 10 | 81 | 4 |
| Spencer, 2002 | Atomoxetine | 53 | 45 | 10 | 81 | 4 |
| Biederman, 2003 | MPH-LA | 63 | 71 | 9 | 77 | 4 |
| Wigal, 2004 | MPH | 41 | 41 | 10 | 88 | 4 |
| Wigal, 2004 | d-MPH | 42 | 41 | 10 | 88 | 4 |
| Kelsey, 2004 | Atomoxetine | 126 | 60 | 10 | 71 | 4 |
| Biederman, 2005 | Modafinil | 163 | 81 | 10 | 71 | 4 |
| Findling, 2005 | OROS MPH | 89 | 85 | 9 | 70 | 4 |
| Weiss, 2005 | Atomoxetine | 99 | 51 | NA | 80 | 4 |
| Swanson, 2006 | Modafinil | 120 | 63 | 10 | 74 | 4 |
| Wilens, 2006 | OROS MPH | 87 | 90 | 15 | 80 | 4 |
| Greenhill, 2006 | Modafinil | 127 | 65 | 10 | 73 | 4 |
| Biederman, 2006 | Modafinil | 48 | 51 | 11 | 74 | 4 |
| Spencer, 2006 | MAS-XR | 26 | 28 | 14 | 64 | 4 |
| Spencer, 2006 | MAS-XR | 27 | 24 | 14 | 64 | 4 |
| Findling, 2006 | MPH | 120 | 39 | 10 | 79 | 4 |
| Findling, 2006 | MPH-MR | 120 | 39 | 10 | 81 | 4 |
| Biederman, 2007 | LDX | 73 | 72 | 9 | 71 | 4 |
| Palumbo, 2008 | MPH | 29 | 30 | 9 | 83 | 4 |
| Palumbo, 2008 | Clonidine | 31 | 30 | 9 | 87 | 4 |
| Biederman, 2008 | GXR | 54 | 61 | 10 | 66 | 4 |
Note: Studies are listed once for each drug evaluated.
d-Amph = dextroamphetamine; d-MPH = dexmethylphenidate; DSM = Diagnostic and Statistical Manual of Mental Disorders; ER = extended-release; GXR = guanfacine extended release; LA = long-acting; LDX = lisdexamfetamine dimesylate; MAS = mixed amphetamine salts; MPH = methylphenidate; MR = modified release; NA = not available; OROS = osmotic-release oral system; XR = extended release.